Medical
-
Zambon said that the Phase 3 PROMIS-II trial of its CMS I-neb inhaled dry powder colistimethate sodium for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult patients with chronic P. aeruginosa lung infections failed… Read more . . .
-
Tonix Pharmaceuticals announced that researchers at the University of Washington have initiated a placebo-controlled Phase 2 trial of Tonix’s TNX-1900 potentiated intranasal oxytocin for social anxiety disorder (SAD). The company said that the study is… Read more . . .
-
Tonix Pharmaceuticals has announced the initiation of the Phase 2 POWER study of its TNX-1900 potentiated oxytocin nasal spray in subjects aged 12-18 whose body mass index (BMI) is in the 95th percentile or higher… Read more . . .
-
Health Canada announced that Pharmascience’s Pendopharm division is recalling one lot of Rhinaris Nasal Mist saline nasal spray after “testing showed that the preservative in the product may not be as effective as expected.” Specifically,… Read more . . .
-
Cipla US has announced a voluntary recall of 6 batches of albuterol MDIs after a report of valve leakage in a single inhaler manufactured in November 2021. The company said that no adverse events have been… Read more . . .
-
Krystal Biotech has announced the initiation of the Phase 1 CORAL-1/US dose escalation trial of its KB407 inhaled gene therapy for the treatment of cystic fibrosis. The Phase 1 study, which is being conducted at the… Read more . . .
-
MannKind Corporation has filed a notice with the US Securities and Exchange Commission (SEC) stating that manufacturing of clinical trial supplies for its planned Phase 2/3 study of MNKD-101 clofazimine inhalation suspension in patients with… Read more . . .
-
According to TFF Pharmaceuticals, the company has received a 3-year Direct to Phase 2 Small Business Innovation Research (SBIR) grant worth ~$2.97 million from the National Institute of Allergy and Infectious Diseases (NIAID) for further… Read more . . .
-
US-based start-up Cystetic Medicines has announced the initiation of a Phase 1 SAD/MAD trial of its CM001 dry powder “molecular prosthetic” in healthy volunteers. The company is developing CM001 for the treatment of cystic fibrosis… Read more . . .
-
MannKind Corporation has announced the initiation of the Phase 4 INHALE-3 study of its Afrezza DPI in type 1 diabetes patients. The trial is expected to enroll approximately 120 type 1 diabetes patients who currently use… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 10: SMI.London 2026, London, UK
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan